Novadaq Technologies Inc.TSX: NDQ

Novadaq announces LUNA highlights from AUA 2006

· Issued by Novadaq Technologies Inc. via CNW
LUNA capable of identifying cavernous nerve primarily responsible for 
erectile function

TORONTO, June 1 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, announced today
that its new product, the LUNA(TM) System, was highlighted at the annual
meeting of the American Urological Association held in Atlanta, Georgia, May
20-25, 2006.
The LUNA System, being developed to enable surgeons to visualize nerves
and lymph nodes during urological applications, was the subject of non-
clinical abstracts presented by authors from the University of Rochester. The
abstract: Intraoperative Visualization of Cavernous Nerves Using Near Infrared
Fluorescence of Indocyanine Green in the Rat, presented by Dr. Dragan J.
Golijani, studied the use of the LUNA System on rat models and demonstrated
conclusively that LUNA is capable of identifying the carnivorous nerve that is
primarily responsible for the erectile function. LUNA is the first system that
has the potential to visualize the nerve bundle surrounding the human prostate
in an intra-operative procedure. This is particularly useful in radical
prostatectomy, as up to 50% of men undergoing such a procedure become impotent
due to inadvertent damage to the surrounding nerve bundle.
"The LUNA system is an evolution of Novadaq's commercial product, the SPY
System," said Dr. Arun Menawat, CEO and President, Novadaq Technologies Inc.
"LUNA has shown the ability to visualize very small nerve bundles in rat
models, as compared to humans. The visualization of human nerve bundles is
therefore not expected to require significant modification to the LUNA
equipment for open prostatectomy cases."
According the American Cancer Society, approximately 250,000 men are
diagnosed with prostate cancer annually in United States alone. This number is
expected to grow in double digits as the population ages. Radical
prostatectomy is currently the most efficacious procedure, but impotence
remains a significant side effect of surgery. Novadaq's LUNA system has the
potential to reduce these side effects. The study will now proceed to human
clinical trials, which are aimed at identifying the nerve bundle surrounding
the prostate. The trial is expected to begin in the second half of 2006.

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery, LUNA is
being developed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

This press release contains certain information that may constitute
forward-looking information within the meaning of securities laws. In some
cases, forward-looking information can be identified by the use of terms such
as "may", "will", "should", "expect", "plan", "anticipate", "believe",
"intend", "estimate", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts. Forward-looking
information may relate to management's future outlook and anticipated events
or results, and may include statements or information regarding the future
financial position, business strategy and strategic goals, research and
development activities, projected costs and capital expenditures, financial
results, research and clinical testing outcomes, taxes and plans and
objectives of or involving Novadaq. Particularly, information regarding future
sales and marketing activities, future revenues and research and development
activities, as well as the Company's plans for each of the SPY System and the
OPTTX System, and the potential for development of an application for the
Company's imaging device in image guided conventional and minimally invasive
nerve-sparing radical prostatectomy, is forward-looking information. Forward-
looking information is based on certain factors and assumptions regarding,
among other things, market acceptance and the rate of market penetration of
Novadaq's SPY System, the clinical results of the use of the SPY System, the
results from clinical tests of the OPTTX System, and potential opportunities
in the AMD treatment market and in image guided conventional and minimally
invasive urological applications including nerve-sparing radical
prostatectomy. While the Company considers these assumptions to be reasonable
based on information currently available to it, they may prove to be
incorrect. Forward looking-information is subject to certain factors,
including risks and uncertainties that could cause actual results to differ
materially from what we currently expect. These factors include risks relating
to the transition from research and development activities to commercial
activities, market acceptance and adoption of the SPY System, dependence on
key suppliers for components of the SPY System and the OPTTX System,
regulatory and clinical risks, risks relating to the protection of
intellectual property, risks inherent in the conduct of research and
development activities, including the risk of unfavorable or inconclusive
clinical trial outcomes, potential product liability, competition and the
risks posed by potential technological advances, and risks relating to
fluctuations in the exchange rate between the US dollar and the Canadian
dollar. You should not place undue importance on forward-looking information
and should not rely upon this information as of any other date. While Novadaq
may elect to, Novadaq is under no obligation and does not undertake to update
this information at any particular time.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases